Related by context. Frequent words. (Click for all words.) 74 Investigational Device Exemption 72 Investigational Device Exemption IDE 59 label multicenter 58 confirmatory Phase 3 57 Pivotal Trial 57 PROPEL trial 57 Phase III pivotal 57 Phase IIa trial 56 BLA submission 55 relapsed refractory multiple myeloma 55 Marketing Authorization Application MAA 54 multicenter clinical 54 supplemental Biologics License Application 54 Pivotal Phase III 53 Completes Enrollment 53 label dose escalation 53 Phase IIb clinical 53 CORTOSS 53 refractory Hodgkin lymphoma 53 Phase 2a clinical 52 Phase III Clinical Trial 52 Phase 2b study 52 Marketing Authorization Application 52 Omigard 52 Zelrix 52 registrational trial 52 pivotal Phase III 52 BrachySil 52 Biologics License Application BLA 52 Phase 2b clinical 52 Phase IIb 52 phase IIa 52 Phase II 52 Special Protocol Assessment 52 Phase Ib 52 randomized Phase III 51 sBLA 51 multicenter randomized double 51 dose escalation trial 51 registrational 51 Fast Track Designation 51 Phase Ib clinical 51 refractory peripheral T 51 Phase IIa clinical trials 51 Phase III clinical 51 MONOVISC 51 Phase 1b clinical 51 Bone Graft 51 IIa clinical trial 50 IND submission 50 Phase III 50 Biologics License Application 50 phase 2a 50 Orphan Drug Status 50 Phase 2a trial 50 Amrubicin 50 placebo controlled clinical 50 Pivotal Phase 50 confirmatory Phase III 50 investigational 50 phase IIb 50 Clinical Study 50 Pirfenidone 49 Genasense R oblimersen 49 double blinded placebo 49 sodium Injection 49 Phase 1b trial 49 lymphoma CTCL 49 alvimopan 49 metastatic hormone refractory 49 Iluvien 49 Fast Track designation 49 pivotal Phase 49 Phase IIb trial 49 Phase III randomized 49 AZX# 49 k clearance 49 placebo controlled randomized 48 Phase IIa 48 FavId 48 nab paclitaxel 48 ThermoDox ® 48 Phase 2a 48 pseudobulbar affect PBA 48 Phase III clinical trials 48 Orphan Drug status 48 Board DSMB 48 Investigational 48 refractory multiple myeloma 48 Gabapentin GR 48 MOZOBIL 48 QNEXA 48 Phase 2b trial 48 Nasdaq VRTX 48 clinical trial 48 Phase 1b 47 FIRAZYR 47 multiple ascending dose 47 Nexavar ® 47 IND enabling 47 Hepatitis C HCV